Figure 1. Study design.
aSulfatinib dose was escalated (until MTD was met) according to a modified Fibonacci 3+3 protocol. Each patient received the assigned dose for the study duration. bThe tumor expansion phase was initiated following determination of the recommended phase II dose based on the results of the dose-escalation phase.